Code Bio Overview

  • Founded
  • 2020
Founded
  • Status
  • Private
  • Employees
  • 7
Employees
  • Latest Deal Type
  • Seed
  • Latest Deal Amount
  • $10M
Latest Deal Amount
  • Investors
  • 6

Code Bio General Information

Description

Developer of a non-viral gene therapy intended to treat serious and life-threatening genetic diseases. The company is leveraging a novel proprietary multivalent synthetic DNA delivery platform, 3DNA, that can overcome many of the challenges inherent with viral-based gene therapies, such as immunogenicity, size and delivery limitations, re-dosability, and manufacturing complexity, enabling physicians to treat patients with rare and prevalent genetic diseases

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
  • 2801 Sterling Drive
  • Hatfield, PA 19440
  • United States
+1 (215) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Code Bio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Seed Round 20-Apr-2021 $10M 0000 0000 Completed Generating Revenue
To view Code Bio’s complete valuation and funding history, request access »

Code Bio Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Seed 0,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
To view Code Bio’s complete cap table history, request access »

Code Bio Executive Team (4)

Name Title Board Seat Contact Info
Robert Getts Ph.D Co-Founder & Chief Technology Officer
Lauren Kaskiel Chief Business Officer
Lori Getts Ph.D Co-Founder & Vice President, Preclinical and Product Development
Brian McVeigh Co-Founder, Chief Executive Officer & Chairman
To view Code Bio’s complete executive team members history, request access »

Code Bio Board Members (8)

Name Representing Role Since
Brian McVeigh Self Co-Founder, Chief Executive Officer & Chairman 000 0000
Dmitry Kuzmin Ph.D 4BIO Capital Partners Board Member 000 0000
Edward Mathers New Enterprise Associates Board Member 000 0000
Joseph Truitt Self Board Member 000 0000
Kathy Rouan Ph.D Self Board Member 000 0000
You’re viewing 5 of 8 board members. Get the full list »

Code Bio Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Code Bio Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
4BIO Capital Partners Venture Capital Minority 000 0000 000000 0
CureDuchenne Ventures Corporate Venture Capital Minority 000 0000 000000 0
New Enterprise Associates Venture Capital Minority 000 0000 000000 0
T1D Fund Venture Capital Minority 000 0000 000000 0
Takeda Ventures Corporate Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 6 investors. Get the full list »